Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments

Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments

Vagus nerve stimulation (VNS) is a long-term adjunctive treatment option in patients with difficult-to-treat depression (DTD). A total of <i>n</i> = 20 patients (mean age 52.6 years) were included in the multicenter, prospective, observational, naturalistic RESTORE-LIFE study and were tr...

Full description

Bibliographic Details
Main Authors:	Erhan Kavakbasi, Helen Bauermeister, Lars Lemcke, Bernhard T. Baune
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Brain Sciences
Subjects:	difficult-to-treat depression treatment-resistant depression esketamine vagus nerve stimulation electroconvulsive therapy medication load
Online Access:	https://www.mdpi.com/2076-3425/14/2/159

Similar Items

Impact of invasive VNS on depression severity and the need of concomitant drug and neuromodulatory treatment dose
by: E. Kavakbasi, et al.
Published: (2022-06-01)

Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
by: Matteo Marcatili, et al.
Published: (2022-09-01)

Treating with esketamine nasal, will increase blood pressure?
by: V. Rosello-Molina, et al.
Published: (2021-04-01)

Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report
by: Charles R. Conway, et al.
Published: (2024-03-01)

Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine
by: Rodolphe H. Lebeau, et al.
Published: (2022-10-01)

A model for the management of difficult to treat depression
by: H. Mcallister-Williams
Published: (2021-04-01)

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
by: Kinza Degerlund Maldi, et al.
Published: (2021-12-01)

How to fail with paired VNS therapy
by: Seth A. Hays, et al.
Published: (2023-09-01)

Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use
by: Helge H. O. Müller, et al.
Published: (2018-04-01)

Viewpoint: Difficult-to-treat depression versus treatment-resistant depression: A new integrative perspective for managing depression
by: Walter Paganin
Published: (2023-01-01)

Is cognitive dysfunction involved in difficult-to-treat depression? Characterizing resistance from a cognitive perspective
by: Clara López-Solà, et al.
Published: (2020-01-01)

VNS parameters for clinical response in Epilepsy
by: Firas Fahoum, et al.
Published: (2022-05-01)

Vagus nerve stimulation in the treatment of nervous system disease: a review article
by: Somayeh Nazari, et al.
Published: (2022-07-01)

Clinical efficacy and tolerability of Esketamine: a case series
by: C. Passani, et al.
Published: (2022-06-01)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
by: D. Hernandez Huerta, et al.
Published: (2022-06-01)

Rethinking treatment-resistant depression to quasi-tenacious depression
by: Shokouh Arjmand, et al.
Published: (2023-01-01)

The Role of Vagus Nerve Stimulation in Depression: What We Know?
by: A. Fraga, et al.
Published: (2022-06-01)

The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
by: Alina Wilkowska, et al.
Published: (2022-11-01)

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
by: Dominika Psiuk, et al.
Published: (2022-09-01)

Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series
by: Hewa Artin, et al.
Published: (2022-06-01)

Vagus Nerve Stimulation (VNS) Therapy System in pharmacoresistant epilepsy: A literature review
by: Moroșanu Valentin, et al.
Published: (2023-09-01)

Adjunctive short- and long-term combination treatment of esketamine and VNS in difficult to treat depression (DTD)
by: E. Kavakbasi, et al.
Published: (2023-03-01)

Vagus Nerve Stimulation as a Treatment for Catatonia: A Hypothesis
by: David Zilles
Published: (2019-02-01)

Treating Depression with Transcutaneous Auricular Vagus Nerve Stimulation: State of the Art and Future Perspectives
by: Jian Kong, et al.
Published: (2018-02-01)

Electroencephalographic Patterns in taVNS: A Systematic Review
by: Anna Carolyna L. Gianlorenco, et al.
Published: (2022-09-01)

Schema therapy versus treatment as usual for outpatients with difficult-to-treat depression: study protocol for a parallel group randomized clinical trial (DEPRE-ST)
by: Ida-Marie T. P. Arendt, et al.
Published: (2024-04-01)

EFFICACY OF ELECTROCONVULSIVE THERAPY IN TREATMENT - RESISTANT DEPRESSION
by: Nida Saleem, et al.
Published: (2018-08-01)

Patients’, Carers’, and the Public’s Perspectives on Electroconvulsive Therapy
by: Chris Griffiths, et al.
Published: (2019-05-01)

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
by: Maria Gałuszko-Węgielnik, et al.
Published: (2023-01-01)

Neural networks and the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation in depression
by: Chun-Hong Liu, et al.
Published: (2020-02-01)

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
by: Lorena Catarina Del Sant, et al.
Published: (2022-12-01)

The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01)

Major depression disorder - etiology and treatment
by: Paulina Czuchryta, et al.
Published: (2023-06-01)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
by: Stephane Borentain, et al.
Published: (2022-12-01)

Locus coeruleus tyrosine hydroxylase positive neurons mediated the peripheral and central therapeutic effects of transcutaneous auricular vagus nerve stimulation (taVNS) in MRL/lpr mice
by: Hongjie Lv, et al.
Published: (2024-01-01)

Precise sound characteristics drive plasticity in the primary auditory cortex with VNS-sound pairing
by: Michael S. Borland, et al.
Published: (2023-09-01)

Vagus nerve stimulation in treatment-resistant depression. Long-term clinical outcomes
by: S. Rosson, et al.
Published: (2021-04-01)

Ingestion of Lactobacillus intestinalis and Lactobacillus reuteri causes depression- and anhedonia-like phenotypes in antibiotic-treated mice via the vagus nerve
by: Siming Wang, et al.
Published: (2020-08-01)

Intractable hiccups after VNS implantation: a case report
by: Susan Zhang Recio, et al.
Published: (2023-08-01)

Predicting response to tVNS in patients with migraine using functional MRI: A voxels-based machine learning analysis
by: Chengwei Fu, et al.
Published: (2022-08-01)